HOME
ABOUT
About Adial
Management
Board of Directors
ADDICTION
Alcohol Addiction
Limitations of Current AUD Therapies
Our Proposed Solution
TECHNOLOGY
Overview
Phase 2b Clinical Trial Results
History of Ondansetron Use for AUD
Strengths and Competitive Advantages
Newsroom
Press Releases
Media
INVESTORS
Overview
Analyst Coverage
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
CONTACT
Contact Us
Sign Up For Email Alerts
HOME
ABOUT
About Adial
Management
Board of Directors
ADDICTION
Alcohol Addiction
Limitations of Current AUD Therapies
Our Proposed Solution
TECHNOLOGY
Overview
Phase 2b Clinical Trial Results
History of Ondansetron Use for AUD
Strengths and Competitive Advantages
INVESTORS
Overview
Analyst Coverage
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
CONTACT
News / Events
Investor Relations
Investor Relations
Overview
Analyst Coverage
News / Events
Press Releases
IR Calendar
Email Alerts
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Recent News
View All News
Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform
July 14, 2021
Adial Announces $5,000,000 Above Market Private Placement at $3.00 Per Share
July 7, 2021
View All News
Email Alerts
Sign up for email alerts for Press Releases & SEC Filings
Sign Up
